- Phase II study of thalidomide in patients with unresectable hepatocellular carcinomaAlbert Y Lin
Department of Medicine, Santa Clara Valley Medical Center, San Jose, California 95128, USA
Cancer 103:119-25. 2005..Therefore, the authors initiated a study to assess the efficacy and toxicity of thalidomide in patients with advanced HCC as primary and secondary endpoints, respectively...
- Phase II study of imatinib in unresectable hepatocellular carcinomaAlbert Y Lin
Department of Medicine, Santa Clara Valley Medical Center, 751 S Bascom Avenue, San Jose, CA 95128, USA
Am J Clin Oncol 31:84-8. 2008..Imatinib, a potent inhibitor of BCR-ABL and c-kit, also inhibits the platelet-derived growth factor receptor tyrosine kinase. The trial was designed to assess the efficacy and safety of imatinib in patients with unresectable HCC...
- Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysisAn Ting T Lu
Santa Clara Valley Medical Center, San Jose, CA 95128, USA
Clin Colorectal Cancer 8:207-14. 2009..We performed a systematic review and meta-analysis of gene expression profiles (GEPs) to assess their utility for risk stratification and prediction of poor outcomes in stage II CRC...
- Impact of initial surgical margins and residual cancer upon re-excision on outcome of patients with localized breast cancerNatalia B Kouzminova
Department of Hematology Oncology, Santa Clara Valley Medical Center, Santa Clara, CA, USA
Am J Surg 198:771-80. 2009..The aim of this study was to assess the impact of initial margins and residual carcinoma found on second surgery on the outcomes of breast cancer patients...